1-3 of 3
Richard Houghten, PhD
Close
Sort by
Journal Articles

Small-Molecule XIAP Inhibitors Derepress Downstream Effector Caspases and Induce Apoptosis of Leukemia Cell Lines and Patient Samples.

Aaron D. Schimmer, MD, PhD, Marcela Gronda, MSc, Zhiliang Wang, PhD, Kate Welsh, PhD, Clemencia Pinilla, PhD, Michael Andreeff, MD, PhD, Wendy D. Schober, Adel Nefzi, PhD, Richard Houghten, PhD, Joseph Brandwein, MD, Mark D. Minden, MD, PhD, Andre Schuh, MD, PhD, Richard A. Wells, MD, PhD, Hans Messner, MD, PhD, John C. Reed, MD, PhD, Bing Z. Carter, PhD
Journal: Blood
Blood (2004) 104 (11): 759.
https://doi.org/10.1182/blood.V104.11.759.759
Published: 2004
Journal Articles

Inhibition of XIAP Renders Newly CD40-Activated Chronic Lymphocytic Leukemia Cells Sensitive to Fas (CD95) Mediated Apoptosis.

Arnon P. Kater, MD, Frank Dicker, PhD, Massimo Mangiola, PhD, Kate Welsh, John Ostresh, PhD, Richard Houghten, PhD, John C. Reed, MD, PhD, Thomas J. Kipps, MD, PhD, Clemencia Pinilla, PhD
Journal: Blood
Blood (2004) 104 (11): 3474.
https://doi.org/10.1182/blood.V104.11.3474.3474
Published: 2004
Journal Articles

Inhibition of XIAP Enhances Specific Cytotoxic T Lymphocyte (CTL) Killing and CD20-Directed Antibody-Dependent Cellular Cytotoxicity of Chronic Lymphocytic Leukemia B Cells.

Arnon P. Kater, MD, Roman Rieger, PhD, Kate Welsh, PhD, Adel Nefzi, PhD, Richard Houghten, PhD, John C. Reed, MD. PhD, Clemencia Pinilla, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 3475.
https://doi.org/10.1182/blood.V104.11.3475.3475
Published: 2004